MX2009001074A - Terapia fotodinamica antimicrobiana. - Google Patents

Terapia fotodinamica antimicrobiana.

Info

Publication number
MX2009001074A
MX2009001074A MX2009001074A MX2009001074A MX2009001074A MX 2009001074 A MX2009001074 A MX 2009001074A MX 2009001074 A MX2009001074 A MX 2009001074A MX 2009001074 A MX2009001074 A MX 2009001074A MX 2009001074 A MX2009001074 A MX 2009001074A
Authority
MX
Mexico
Prior art keywords
photosensitizer
vector
ethylene glycol
conjugates
units
Prior art date
Application number
MX2009001074A
Other languages
English (en)
Inventor
Burkhard Gitter
Nikolay E Nifantiev
Dmitri V Yashunsky
Original Assignee
Ceramoptec Ind Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Ceramoptec Ind Inc filed Critical Ceramoptec Ind Inc
Publication of MX2009001074A publication Critical patent/MX2009001074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Los conjugados moleculares antimicrobianos para el tratamiento y prevención de enfermedades infecciosas causadas por microorganismos patogénicos en humanos y animales se proporcionan. La clave para estos conjugados es un espaciador especial que conecta al menos un fotosensibilizador a un microorganismo receptor (vector) el cual, a su vez, se une selectivamente con la superficie de un microorganismo confiriéndole foto-destrucción después de la irradiación. Los espaciadores que tienen estructura hidrofílica tales como unidades de etilenglicol y amino carboxilo y unidades de etilenglicol con extremo protegido deben de utilizarse para enlazar el vector al fotosensibilizador. En una modalidad preferida un espaciador tendría al menos tres unidades de etilenglicol de extremo protegido con un grupo carboxilo en un extremo y un grupo amino al otro extremo. La presente invención efectivamente trabaja para combatir infección bacterial en ambientes relacionados con pacientes reales en donde la sangre, el suero y otros fluidos corporales son siempre presentes o al menos cerca. Los espaciadotes de longitud seleccionada y estructura, en modalidades preferidas, son utilizados para enlazar el vector al fotosensibilizador. Estos conjugados se encontraron ser muy efectivos en combatir una infección bacterial en ambientes relacionados con pacientes reales en donde la sangre, el suero y otros fluidos corporales son siempre presentes o al menos cerca. Un método de uso también es proporcionado.
MX2009001074A 2006-07-27 2007-07-27 Terapia fotodinamica antimicrobiana. MX2009001074A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
PCT/US2007/016951 WO2009014524A2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Publications (1)

Publication Number Publication Date
MX2009001074A true MX2009001074A (es) 2009-06-05

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001074A MX2009001074A (es) 2006-07-27 2007-07-27 Terapia fotodinamica antimicrobiana.

Country Status (4)

Country Link
EP (1) EP2049105A4 (es)
BR (1) BRPI0714667A8 (es)
MX (1) MX2009001074A (es)
WO (1) WO2009014524A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022001416A (es) 2019-08-02 2022-05-26 Koite Health Oy Metodo para mejorar la accion antimicrobiana de los antibioticos administrados sistemicamente.
CN114053406B (zh) * 2021-11-23 2022-12-09 华中科技大学 一种多功能光热纳米杀菌材料及制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462070B1 (en) * 1997-03-06 2002-10-08 The General Hospital Corporation Photosensitizer conjugates for pathogen targeting
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
CA2444483A1 (en) * 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
WO2005067644A2 (en) * 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Also Published As

Publication number Publication date
BRPI0714667A8 (pt) 2016-10-18
WO2009014524A3 (en) 2020-10-15
BRPI0714667A2 (pt) 2013-08-06
EP2049105A2 (en) 2009-04-22
WO2009014524A2 (en) 2009-01-29
EP2049105A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CY1114577T1 (el) Αποτροπη και θεραπεια υπο-κλινικης pcvd
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
NI202000023A (es) Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas.
EP2494059A4 (en) USE OF METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY
BR112013001577A2 (pt) conjugados de carboidrato e dihidorxiclorina e clorina <225>-funcionalizada e respectivos usos e método para eliminar microorganismos em ambiente de paciente real
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
CY1112851T1 (el) Μεθοδος προληψης ή θεραπειας μολυνσης μ. τuβεrculosis
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
DK2079481T3 (da) Vaccinepeptidkombinationer mod katteallergi
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
EA201101477A1 (ru) Органические соединения и их применение
CY1118835T1 (el) Αντισωμα anti-fgf23 και φαρμακευτικη συνθεση που το περιλαμβανει
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
BRPI0518255A2 (pt) mÉtodos de tratamento ou prevenÇço de uma lesço do sistema nervoso central, para reduzir ou evitar um efeito adverso, e composiÇço farmacÊutica
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
AR106538A1 (es) Métodos y composiciones para el tratamiento de la amiloidosis
GT200500063A (es) Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: BIOLITEC PHARMA MARKETING LTD.*

FG Grant or registration